These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1127230)

  • 1. Development and inhibition of cytotoxic antibody against spontaneous murine breast cancer.
    Stolfi RL; Fugmann RA; Stolfi LM; Martin DS
    J Immunol; 1975 Jun; 114(6):1824-30. PubMed ID: 1127230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbodiimide enhancement of complement-dependent antibody-mediated tumor cell lysis in vitro and antitumor activity in vivo.
    Fawwaz RA; Tenforde TS; Mehlberg WH
    Cancer Res; 1975 Mar; 35(3):679-86. PubMed ID: 1116128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression by cytosine arabinoside of serum-blocking factors of cell-mediated immunity to syngeneic transplants of mouse mammary tumors.
    Heppner GH; Calabresi P
    J Natl Cancer Inst; 1972 Apr; 48(4):1161-7. PubMed ID: 5023677
    [No Abstract]   [Full Text] [Related]  

  • 4. LY-2+ effectors cytotoxic for syngeneic tumor cells: generation by allogeneic stimulation and by supernatants from mixed leukocyte cultures.
    Hurrell SM; Zarling JM
    J Immunol; 1983 Aug; 131(2):1017-23. PubMed ID: 6223084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activity of regional nodes in the evolution of immune responses to allogeneic and isogeneic tumors.
    Barna B; Deodhar SD
    Cancer Res; 1975 Apr; 35(4):920-6. PubMed ID: 1116149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
    Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
    J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo mechanisms of alloreactivity. III. Development of donor-specific antibody in sponge matrix allografts.
    Sirinek LP; Zinn NE; Ferguson RM; Orosz CG
    Transplantation; 1986 Mar; 41(3):349-56. PubMed ID: 3952801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunity to the T1699 murine mammary tumor. I. Thymic influence and long-term effect of irradiation on the humoral response.
    Parthenais E; Haskill S
    J Immunol; 1979 Sep; 123(3):1329-33. PubMed ID: 381522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to a syngeneic mammary adenocarcinoma. III. Development of memory and suppressor functions modulating cellular cytotoxicity.
    Kuperman O; Fortner GW; Lucas ZJ
    J Immunol; 1975 Nov; 115(5):1282-7. PubMed ID: 1176776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of non-complement-fixing, blocking factors by lysosomal extract treatment of cytotoxic anti-tumor antibodies.
    Dauphinee MJ; Talal N; Witz IP
    J Immunol; 1974 Sep; 113(3):948-53. PubMed ID: 4413555
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune response of BALB/c X DBA/2F1 mice to a tumor allograft during pyran copolymer-induced tumor enhancement.
    Schultz RM; Woods WA; Mohr SJ; Chirigos MA
    Cancer Res; 1976 May; 36(5):1641-6. PubMed ID: 1268825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune status of autochthonous and adoptively protected mice toward spontaneous and chemically induced tumors.
    Basombrío MA; Prehn RT
    Cancer Res; 1972 Nov; 32(11):2545-50. PubMed ID: 5082598
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on the cytolytic attack mechanism of the cytotoxic T lymphocyte (CTL): preparation of antisera against cellfree cytosolic extracts of a CTL clone capable of blocking the lethal hit stage of CTL cytolysis and analysis of the cytolytic structure.
    Hiserodt JC
    J Immunol; 1985 Jul; 135(1):53-62. PubMed ID: 3158707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mouse rosette forming cells in transplantation immunity].
    Brondz BD; Eliseeva LS; Kotomina IF; Egorova SG
    Tsitologiia; 1974 Jan; 16(1):74-81. PubMed ID: 4142816
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune response to inactivated syngeneic mammary adenocarcinoma cells. I. Role and regulation of antibody synthesis in DBA/2 mice.
    DeLustro F; Haskill JS
    J Natl Cancer Inst; 1980 Jan; 64(1):125-30. PubMed ID: 6928037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in lymphoreticular tissues during growth of a murine adenocarcinoma. 3. Plaque-forming cell response in lymph nodes and spleen.
    Rowland GF; Edwards AJ; Hurd CM; Sumner MR
    J Natl Cancer Inst; 1971 Aug; 47(2):321-7. PubMed ID: 4934422
    [No Abstract]   [Full Text] [Related]  

  • 18. Natural history of mouse syngeneic lymphoma. Morphologic and immunologic aspects.
    Jurin M; Drewinko B
    Am J Pathol; 1974 Nov; 77(2):213-36. PubMed ID: 4614670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response to a mammary adenocarcinoma. V. Sera from tumor-bearing rats contain multiple factors blocking cell-mediated cytotoxicity.
    Huber SA; Lucas ZJ
    J Immunol; 1978 Dec; 121(6):2485-9. PubMed ID: 722081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of anti-plasma cell serum on B cells.
    Nariuchi H; Matuhasi T
    J Immunol; 1974 Feb; 112(2):462-7. PubMed ID: 4205202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.